Copy to clipboard 
Royal Biologics announced the FDA 510(k) regulatory clearance and U.S. commercial launch of MAXX-BMC. MAXX-BMC is a bone marrow aspirate concentration system that provides users an optimal sample of concentrated bone marrow aspirate from a patient point of care. Royal’s patented “Lead Screw” technology in its Maxx concentration device allows users to develop a customized sample for use during orthopedic and sports medicine surgical procedures. MAXX-BMC is the latest addition featured in Royal Biologics’ industry-leading portfolio of Advanced Cellular Technologies & Enhanced Autologous Healing solutions.
Lead Screw technology allows clinicians to pinpoint precise and accurate areas of the “Buffy Coat” fraction (growth factor layer) of bone marrow aspirate in a matter of seconds post concentration. Maxx-BMC provides up to two concentration cycles in eight minutes.
Royal Biologics’ Enhanced Autologous Healing and Advanced Cellular Portfolio comprises five unique systems: FIBRINET (Platelet Rich Fibrin Matrix), OSTEO-SPIN, MAXX-Cell (bone marrow harvester), MAXX-PRP (Platelet Rich Plasma), and MAXX-BMC (Bone Marrow Aspirate Concentrate).
